Rituximab combined with chemotherapy and interferon in follicular lymphoma patients : results of the GELA-GOELAMS FL2000 studySALLES, Gilles; MOUNIER, Nicolas; AUDHUY, Bruno et al.Blood. 2008, Vol 112, Num 13, pp 4824-4831, issn 0006-4971, 8 p.Article

Single versus double autologous stem-cell transplantation for multiple myelomaATTAL, Michel; HAROUSSEAU, Jean-Luc; VOILLAT, Laurent et al.The New England journal of medicine. 2003, Vol 349, Num 26, pp 2495-2502, issn 0028-4793, 8 p.Article

Acute intoxication with nevirapine in an HIV-1-infected patient: clinical and pharmacokinetic follow upELENS, Laure; HAUFROIDA, Vincent; DOYEN, Chantal et al.AIDS (London). 2009, Vol 23, Num 10, pp 1291-1293, issn 0269-9370, 3 p.Article

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06) : a randomised trialFACON, Thierry; YVES MARY, Jean; DIB, Mamoun et al.Lancet (British edition). 2007, Vol 370, Num 9594, pp 1209-1218, issn 0140-6736, 10 p.Article

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma : the GELF-94 randomized study from the groupe d'etude des lymphomes de l'adulte (GELA). CommentaryVAN BESIEN, Koen; SEBBAN, Catherine; DOYEN, Chantal et al.Blood. 2006, Vol 108, Num 8, issn 0006-4971, 2496-2497,2540-2544 [7 p.]Article

Unusual growth within a meningioma (leukemic infiltrate)SONET, Anne; HUSTIN, Jean; BOSLY, Andre et al.The American journal of surgical pathology. 2001, Vol 25, Num 1, pp 127-130, issn 0147-5185Article

The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcomeVEKEMANS, Marie-Christiane; LEMMENS, Heidi; BAUWENS, Deborah et al.British journal of haematology. 2010, Vol 149, Num 6, pp 901-904, issn 0007-1048, 4 p.Article

Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component useCLAUDE OSSELAER, Jean; DOYEN, Chantal; CORASH, Laurence et al.Transfusion (Philadelphia, PA). 2009, Vol 49, Num 7, pp 1412-1422, issn 0041-1132, 11 p., 1Article

Follicular lymphoma International Prognostic IndexSOLAL-CELIGNY, Philippe; ROY, Pascal; COIFFIER, Bertrand et al.Blood. 2004, Vol 104, Num 5, pp 1258-1265, issn 0006-4971, 8 p.Article

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trialMOREAU, Philippe; ATTAL, Michel; KETTERER, Nicolas et al.Blood. 2011, Vol 117, Num 11, pp 3041-3044, issn 0006-4971, 4 p.Article

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myelomaMOREAU, Philippe; AVET-LOISEAU, Herve; LEPEU, Gerard et al.Blood. 2011, Vol 118, Num 22, pp 5752-5758, issn 0006-4971, 7 p.Article

Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 TrialHULIN, Cyrille; FACON, Thierry; LENAIN, Pascal et al.Journal of clinical oncology. 2009, Vol 27, Num 22, pp 3664-3670, issn 0732-183X, 7 p.Article

Prognosis of hematologic malignancies does not predict intensive care unit mortalityMASSION, Paul B; DIVE, Alain M; DOYEN, Chantal et al.Critical care medicine. 2002, Vol 30, Num 10, pp 2260-2270, issn 0090-3493, 11 p.Article

Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 TrialsHAROUSSEAU, Jean-Luc; AVET-LOISEAU, Herve; KETTERER, Nicolas et al.Journal of clinical oncology. 2009, Vol 27, Num 34, pp 5720-5726, issn 0732-183X, 7 p.Article

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapyFACON, Thierry; MARY, Jean-Yves; HAROUSSEAU, Jean-Luc et al.Blood. 2006, Vol 107, Num 4, pp 1292-1298, issn 0006-4971, 7 p.Article

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. CommentaryMERLINI, Giampaolo; ATTAL, Michel; PEGOURIE, Brigitte et al.Blood. 2006, Vol 108, Num 10, issn 0006-4971, 3235-3236,3289-3294 [8 p.]Article

Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin BOFFNER, Fritz; KRCMERY, Vladimir; MOREAU, Philippe et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 12, pp 4808-4812, issn 0066-4804, 5 p.Article

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopeniaROBAK, Tadeusz; WINDYGA, Jerzy; PEREZ RUS, Gloria et al.Blood. 2012, Vol 120, Num 18, pp 3670-3676, issn 0006-4971, 7 p.Article

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationGARDERET, Laurent; IACOBELLI, Simona; MILONE, Giuseppe et al.Journal of clinical oncology. 2012, Vol 30, Num 20, pp 2475-2482, issn 0732-183X, 8 p.Article

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma : final results of the prospective and randomized IFM 99-04 protocolMOREAU, Philippe; HULLIN, Cyrille; BERTHOU, Christian et al.Blood. 2006, Vol 107, Num 1, pp 397-403, issn 0006-4971, 7 p.Article

Comparison of 200 mg/m² melphalan and 8 Gy total body irradiation plus 140 mg/m² melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trialMOREAU, Philippe; FACON, Thierry; JAUBERT, Jérome et al.Blood. 2002, Vol 99, Num 3, pp 731-735, issn 0006-4971Article